Evidence map›Paper›PMID 42039269›Full record

ReviewActa pharmaceutica Sinica. B2026

Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives.

Wenfei Xu, Shuxuan Zhu, Zhaogang Sun, Jun Ye, Hongqian Chu

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenfei XuTranslational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Shuxuan ZhuTranslational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Zhaogang SunTranslational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Jun YeState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Hongqian ChuTranslational Medicine Center, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer immunotherapy is an innovative treatment approach that leverages the immune system's ability to identify and attack tumor cells. Its goal is to initiate or re-establish the tumor-immune cycle. However, challenges such as limited response rates and adverse immune responses have hindered the further application and advancement of this therapy. Recent progress in nanomedicine, particularly in self-assembled nanomaterials, has attracted significant attention due to their excellent physical and chemical properties. Self-assembled nanoplatforms can be designed to selectively deliver immunoadjuvants, therapeutic drugs, photosensitizers, and sonosensitizers, overcoming the limitations of traditional monotherapies. By utilizing these self-assembled nanoplatforms to synergistically combine cancer immunotherapy with photodynamic therapy (PDT), photothermal therapy (PTT), radiotherapy (RT), and sonodynamic therapy (SDT), it becomes possible to amplify and enhance the immune responses elicited by these localized treatments, thus offering new strategies for cancer therapy. In this review, we discussed various immunotherapy platforms based on the self-assembly of nucleic acids, peptides and proteins, metals, and supramolecules. We also highlight the significant research advancements over the past three years in the use of self-assembled nanomaterials for combination therapies centered on immunotherapy, aiming to provide valuable insights and references for ongoing tumor therapy research.

Indexed as

Cancer immunotherapyCombination therapyMetalsNanoplatformsNucleic acidsPeptides and proteinsSelf-assemblySupramolecules

Identifiers

PMID42039269
PMCPMC13104679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.